Staphylococcal Skin Infections Clinical Trial
Official title:
A Multicentre, Open Label, Uncontrolled Clinical Trial to Evaluate Efficacy and Safety of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections (cSSTI) Caused by Methicillin-resistant Staphylococcus Aureus (MRSA)
NCT number | NCT00463801 |
Other study ID # | CCBC134AIT01 |
Secondary ID | |
Status | Terminated |
Phase | Phase 4 |
First received | April 19, 2007 |
Last updated | March 22, 2011 |
Start date | January 2007 |
Verified date | March 2011 |
Source | Novartis |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: The Italian Medicines Agency |
Study type | Interventional |
This study will evaluate the safety and efficacy of daptomycin against complicated skin and skin-structure infections in adults
Status | Terminated |
Enrollment | 52 |
Est. completion date | |
Est. primary completion date | November 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Subjects with a diagnosis of complicated skin and skin-structure infections (cSSTI) defined as infection normally requiring surgical/local debridement of sufficient severity to warrant hospitalization and intravenous antimicrobial treatment - Infection to be due to Gram-positive bacteria - Hospitalized subjects - Written informed consent - Female patients of childbearing potential must have a negative pregnancy test urine or serum at baseline and must use effective contraception throughout the study period. Exclusion criteria: - Complicated skin and skin-structure infections of the following categories: - Infected burns - Severely impaired arterial blood supply - Decubitus ulcers - Infected diabetic foot ulcers associated with osteomyelitis - Infected human or animal bites - Perirectal abscess - Necrotising fasciitis or gangrene - Infections expected to require more than 14 days of intravenous antimicrobial therapy - Skin and/or skin structure infection that can be treated by surgery alone - Infections associated with a permanent prosthetic device that will not be removed within 2 days of study enrollment - Uncomplicated skin or soft tissue infection - Documented bacteremia at baseline - Concomitant infection nearby the site of infection at baseline, potentially interfering with the evaluations - Hospitalization for conditions related to rhabdomyolysis - Human immunodeficiency virus (HIV) with cluster of differentiation (CD) < 200 or < 14% - Immune function alterations - Lack of sufficient purulent material for culture and Gram test - Systemic or local antibiotic administration with known anti-Gram positive activity in the preceding 48 hours - Complicated skin and soft tissue infections (cSSTI) known or believed to be related to fungal, parasitic or viral infection - Pneumonia - Local or systemic known or suspected allergy to daptomycin - Creatinine clearance < 30 mL/min - Severe liver damage (Child-Pugh class C) or Alanine transaminase (ALT) and/or Aspartate aminotransferase (AST) > 3 x Upper limit of normal (ULN) and/or bilirubin > 1.5 x ULN - Use of any experimental drugs in the preceding 30 days - Severe medical conditions that in the investigator's opinion could counter indicate participation in the study |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Italy | Novartis Italy | Novartis Italy | |
Italy | Novartis Italy | Saronno |
Lead Sponsor | Collaborator |
---|---|
Novartis |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Participants With Clinical Success at the Day 7 (D7) and Day 14 (D14) Visit After Treatment Start | Primary objective of the study was to evaluate the efficacy of intravenous (IV) daptomycin in the treatment of complicated skin and soft tissue infections (cSSTI) caused by methicillin-resistant Staphylococcus aureus (MRSA), as assessed by measuring the clinical success rate achieved at the day 7 and day 14 visit (D7, D14) after treatment start. Clinical success is defined as complete resolution of signs and symptoms of infection, or clinical improvement, i.e. partial resolution of signs and symptoms so that no further antibacterial treatment was required. | at Day 7 and 14 | No |
Secondary | Efficacy Assessed as Success After 4, 7, 10 and 14 Days of Treatment With Daptomycin on Infecting Gram Positive Bacteria | To evaluate the microbiological efficacy of intravenous (IV) daptomycin in the treatment of complicated skin and soft tissue infections (cSSTI) caused by methicillin-resistant Staphylococcus aureus (MRSA), as assessed by measuring the proportion of patients achieving eradication of the Gram-positive baseline organisms at the study visits on D4, D7, D10, and D14. Microbiological success is documented eradication of baseline Gram-positive organism or presumed eradication defined as clinical success and no culture performed because of absence of drainage or other material for culture. | At day 4, 7, 10 and 14 | No |
Secondary | Efficacy Assessed as Percentage of Patients With Clinical Success at Day 4 and 10 | To evaluate the efficacy of intravenous (IV) daptomycin in the treatment of complicated skin and soft tissue infections (cSSTI) caused by methicillin-resistant Staphylococcus aureus (MRSA), as assessed by measuring the clinical success rate achieved at the interim visits on day 4 (D4) and day 10 (D10) after treatment start. Clinical success is defined as complete resolution of signs and symptoms of infection, or clinical improvement, i.e. partial resolution of signs and symptoms so that no further antibacterial treatment was required. | At day 4 and 10 | No |
Secondary | Efficacy Assessed by Duration of Treatment With Daptomycin Intravenous | At day 14 | No | |
Secondary | Efficacy Assessed by Time of Resolution of Infection | Time to resolution of signs and symptoms of infection, time to resolution of fever (oral or tympanic temperature =37.5°C). | At day 14 | No |
Secondary | Safety Assessed by Hematological and Biochemical Tests, Urinalysis, and Recording and Follow-up of Emerging AE and SAE | At day 14 | Yes | |
Secondary | Evaluated Resource Utilization and Calculated Overall Treatment Cost (Including Treatment Period and Follow-up Period) | at day 14 and follow up day i.e. day 30 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01419184 -
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
|
Phase 4 | |
Completed |
NCT00210899 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Recruiting |
NCT02566928 -
Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence
|
Phase 4 | |
Completed |
NCT00228982 -
Ceftobiprole in the Treatment of Resistant Staphylococcus Aureus Skin and Skin Structure Infections
|
Phase 3 | |
Completed |
NCT01105767 -
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
|
N/A | |
Completed |
NCT01030731 -
Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal Disease
|
Phase 1 | |
Completed |
NCT00475930 -
Chlorhexidine Impregnated Cloths to Prevent Skin and Soft Tissue Infections in Marine Officer Candidates
|
N/A | |
Completed |
NCT02814916 -
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
|
Phase 3 | |
Completed |
NCT00513799 -
The Natural History of Community-Associated MRSA Infections and Decolonization Strategies
|
N/A | |
Completed |
NCT00737269 -
A Complicated Skin and Soft-tissue Infection Patient Registry
|
Phase 4 | |
Completed |
NCT00719810 -
Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
|
Phase 2 | |
Completed |
NCT01026740 -
Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT00492271 -
First Time in Man Trial for Friulimicin B
|
Phase 1 | |
Completed |
NCT00731783 -
Staphylococcus Aureus Decolonization Study
|
N/A | |
Completed |
NCT01018641 -
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults
|
Phase 1 | |
Completed |
NCT02582203 -
Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA
|
Phase 4 | |
Completed |
NCT00646958 -
Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
|
Phase 2 | |
Completed |
NCT00514527 -
A Study for Patients With Complicated Skin and Skin Structure Infections
|
Phase 2 | |
Completed |
NCT01026636 -
A Single-Dose Pharmacokinetics and Safety Study of Ceftobiprole in Pediatric Patients =3 Months to <18 Years of Age
|
Phase 1 | |
Completed |
NCT01026558 -
A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese Patients
|
Phase 1 |